

Patient Information **Please include copy of prescription and medical insurance card, front and back**

Patient Name: _____ Date of Birth: _____
Street Address: _____ Phone: _____
City, State, Zip: _____ Allergies: _____

Prescriber Information

Prescriber Name: _____ NPI: _____
Specialty: _____ Phone: _____
Office Street Address: _____ Fax: _____
City, State, Zip: _____ Office Contact: _____

Patient Medical Information **Please include copies of any pertinent clinical notes and lab work**

Diagnosis (ICD-10): K50.0 (Crohn's Disease of the Small Intestine) K51.0 (Ulcerative Pancolitis) K51.8 (Other Ulcerative Colitis)
 K50.1 (Crohn's Disease of the Large Intestine) K51.2 (Ulcerative Procolitis) K51.9 (Ulcerative Colitis, unspecified)
 K50.8 (Crohn's Disease of Both Intestines) K51.3 (Ulcerative Rectosigmoiditis) Other _____
 K50.9 (Crohn's Disease, unspecified) K51.5 (Left Sided Colitis) _____

Diagnosis Date: _____ Date of negative TB Test: _____ Date of negative chest X-ray (if TB positive): _____

Previous and/or Current Medications Used to Treat this Diagnosis:

Medication Name(s)	Current Use	Start Date	End Date	Discontinue Reason (if stopped)
_____	<input type="checkbox"/>	_____	_____	<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____
_____	<input type="checkbox"/>	_____	_____	<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____
_____	<input type="checkbox"/>	_____	_____	<input type="checkbox"/> Failed <input type="checkbox"/> Other Explanation: _____

Drug Name	Dosing	Quantity	Form	Refills
<input type="checkbox"/> Cimzia (certolizumab)	Initial (if applicable) <input type="checkbox"/> Inject 400 mg subcutaneously at weeks 0, 2, and 4 Maintenance <input type="checkbox"/> Inject 400 mg subcutaneously every 4 weeks	<input type="checkbox"/> #6 (200 mg / 1 mL) <input type="checkbox"/> #2 (200 mg / 1 mL)	<input type="checkbox"/> PFS <input type="checkbox"/> Vial <input type="checkbox"/> PFS <input type="checkbox"/> Vial	No Refills Refills: _____
<input type="checkbox"/> Humira (adalimumab)	Initial (if applicable) <input type="checkbox"/> Inject 160 mg subcutaneously on Day 1, then 80 mg on Day 15 <input type="checkbox"/> Inject 80 mg subcutaneously on Day 1, 80 mg on Day 2, 80 mg on Day 15 Maintenance <input type="checkbox"/> Inject 40 mg subcutaneously every other week (starting day 29)	<input type="checkbox"/> #1 (80 mg/0.8mL Crohn's Starter Kit - citrate-free) <input type="checkbox"/> #1 (40 mg/0.8mL Crohn's Starter Kit) <input type="checkbox"/> #2 (40 mg/0.4mL) - Citrate Free <input type="checkbox"/> #2 (40 mg/0.8mL)	<input type="checkbox"/> Pen Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> PFS	No Refills Refills: _____
<input type="checkbox"/> Rinvoq (upadacitinib)	Initial (if applicable) <input type="checkbox"/> Take 45 mg by mouth once daily for 8 weeks Maintenance <input type="checkbox"/> Take 15 mg by mouth once daily <input type="checkbox"/> Take 30 mg by mouth once daily	<input type="checkbox"/> #56 tablets (45 mg tablet) <input type="checkbox"/> #30 (15 mg tablet) <input type="checkbox"/> #30 (30 mg tablet)	Tablet Tablet	No Refills Refills: _____
<input type="checkbox"/> Simponi (golimumab)	Initial (if applicable) <input type="checkbox"/> Inject 200 mg subcutaneously at week 0 and 100mg at week 2 Maintenance <input type="checkbox"/> Inject 100 mg subcutaneously every 4 weeks	<input type="checkbox"/> #3 (100 mg / 1 mL) <input type="checkbox"/> #4 (100 mg / 1 mL)	<input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS <input type="checkbox"/> Auto Injector <input type="checkbox"/> PFS	No Refills Refills: _____
<input type="checkbox"/> Stelara (ustekinumab)	Initial (if applicable) <input type="checkbox"/> Infuse 260 mg intravenously over no less than one hour (≤55kg) <input type="checkbox"/> Infuse 390 mg intravenously over no less than one hour (55-85kg) <input type="checkbox"/> Infuse 520 mg intravenously over no less than one hour (≥85kg) Maintenance (Starting 8 weeks after initial infusion, if applicable) <input type="checkbox"/> Inject 90 mg subcutaneously every 8 weeks	<input type="checkbox"/> #2 (130 mg / 26 mL) <input type="checkbox"/> #3 (130 mg / 26 mL) <input type="checkbox"/> #4 (130 mg / 26 mL) <input type="checkbox"/> #1 (90 mg / 1 mL)	Vials PFS	No Refills Refills: _____
<input type="checkbox"/> Xeljanz (tofacitinib)	Initial (if applicable) <input type="checkbox"/> Take 10 mg by mouth twice daily for 8 weeks Maintenance <input type="checkbox"/> Take 5 mg by mouth twice daily <input type="checkbox"/> Take 10 mg by mouth twice daily	<input type="checkbox"/> #60 (10 mg tablet) <input type="checkbox"/> #60 (5 mg tablet) <input type="checkbox"/> #60 (10 mg tablet)	Tablet Tablet	Refills: _____ Refills: _____
<input type="checkbox"/> Skyrizi (risankizumab)	Initial (if applicable) <input type="checkbox"/> Infuse 600 mg intravenously over at least one hour at weeks 0, 4, and 8 Maintenance <input type="checkbox"/> Inject 360 mg subcutaneously at week 12, then every 8 weeks	<input type="checkbox"/> #3 (600 mg / 10 mL) <input type="checkbox"/> #1 (360 mg / 2.4 mL)	Vial Prefilled cartridge	No Refills Refills: _____
<input type="checkbox"/> Zeposia (ozanimod)	Initial (if applicable) <input type="checkbox"/> Take 0.23 mg by mouth once daily on days 1-4, then 0.46 mg once daily on days 5-7 Alternate Initial (if applicable) <input type="checkbox"/> Take 0.23 mg by mouth once daily on days 1-4, then 0.46 mg once daily on days 5-7, then 0.92 mg once daily starting on day 8 Maintenance <input type="checkbox"/> Take 0.92 mg by mouth once daily	<input type="checkbox"/> #1 (7-day starter pack) <input type="checkbox"/> #1 (37-day starter kit - 7-day starter pack + 0.92 mg capsules) <input type="checkbox"/> #30 (0.92 mg capsule)	Capsule Starter Pack Capsule Starter Kit Capsule	No Refills No Refills Refills: _____

Prescriber Signature (No Stamps Permitted)

By signing below, I authorize Memorial Hermann Specialty Pharmacy to serve as my designated agent, if needed, to initiate and execute any applicable authorization processes with medical and prescription insurance companies. To prohibit generic substitution write "brand necessary" or "brand medically necessary" on the face of the prescription in your own handwriting.

Prescriber's Signature : _____ Date: _____

Confidentiality Notice- Warning: Unauthorized interception of this fax communication could be a violation of federal and state law. The documents accompanying this fax transmission may contain information that is legally privileged. The information is intended only for use by the recipient. You are hereby notified that any disclosure, copying, distribution, or taking of any action on the contents of this faxed information is strictly prohibited. If you have received this information in error, please immediately notify sender by telephone to arrange for the return of the original documents.